N Niikura1, A Tomotaki2, H Miyata2, T Iwamoto3, M Kawai4, K Anan5, N Hayashi6, K Aogi7, T Ishida8, H Masuoka9, K Iijima10, S Masuda11, K Tsugawa12, T Kinoshita13, S Nakamura14, Y Tokuda15. 1. Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Isehara niikura@is.icc.u-tokai.ac.jp. 2. Department of Healthcare Quality Assessment, Graduate School of Medicine, The University of Tokyo, Tokyo. 3. Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama. 4. Department of Breast Surgery, Miyagi Cancer Center, Natori. 5. Department of Surgery, Kitakyushu Municipal Medical Center, Kitakyushu. 6. Department of Breast Surgery, St Luke's International Hospital, Tokyo. 7. Department of Breast Surgery, Shikoku Cancer Center, Matsuyama. 8. Department of Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai. 9. Sapporo-kotoni Breast Clinic, Sapporo. 10. Department of Breast Oncology, Cancer Institute Hospital, Tokyo. 11. Department of Pathology, Nihon University School of Medicine, Tokyo. 12. Division of Breast and Endocrine Surgery, Department of Surgery, St Marianna University School of Medicine, Kawasaki. 13. Department of Breast Surgery, National Cancer Center Hospital, Tokyo. 14. Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, Tokyo, Japan. 15. Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Isehara.
Abstract
BACKGROUND: We investigate rates of pathologic complete response (pCR) and tumor expression of ER, PgR, HER2 discordance after neoadjuvant chemotherapy using Japanese breast cancer registry data. PATIENTS AND METHODS: Records of more than 300,000 breast cancer cases treated at 800 hospitals from 2004 to 2013 were retrieved from the breast cancer registry. After data cleanup, we included 21,755 patients who received neoadjuvant chemotherapy and had no distant metastases. pCR was defined as no invasive tumor in the breast detected during surgery after neoadjuvant chemotherapy. HER2 overexpression was determined immunohistochemically and/or using fluorescence in situ hybridization. RESULTS: pCR was achieved in 5.7% of luminal tumors (n = 8730), 24.6% of HER2-positive tumors (n = 4403), and 18.9% of triple-negative tumors (n = 3660). Among HER2-positive tumors, pCR was achieved in 31.6% of ER-negative tumors (n = 2252), 17.0% of ER-positive ones (n = 2132), 31.4% of patients who received trastuzumab as neoadjuvant chemotherapy (n = 2437), and 16.2% of patients who did not receive trastuzumab (n = 1966). Of the 2811 patients who were HER2-positive before treatment, 601 (21.4%) had HER2-negative tumors after neoadjuvant chemotherapy, whereas 340 (3.4%) of the 9947 patients with HER2-negative tumors before treatment had HER2-positive tumors afterward. Of the 10,973 patients with ER-positive tumors before treatment, 499 (4.6%) had ER-negative tumors after neoadjuvant chemotherapy, whereas 519 (9.3%) of the 5607 patients who were ER-negative before treatment had ER-positive tumors afterward. CONCLUSION: We confirmed that loss of HER2-positive status can occur after neoadjuvant treatment in patients with primary HER2-positive breast cancer. We also confirmed that in practice, differences in pCR rates between breast cancer subtypes are the same as in clinical trials. Our data strongly support the need for retest ER, PgR, HER2 of surgical sample after neoadjuvant therapy in order to accurately determine appropriate use of targeted therapy.
BACKGROUND: We investigate rates of pathologic complete response (pCR) and tumor expression of ER, PgR, HER2 discordance after neoadjuvant chemotherapy using Japanese breast cancer registry data. PATIENTS AND METHODS: Records of more than 300,000 breast cancer cases treated at 800 hospitals from 2004 to 2013 were retrieved from the breast cancer registry. After data cleanup, we included 21,755 patients who received neoadjuvant chemotherapy and had no distant metastases. pCR was defined as no invasive tumor in the breast detected during surgery after neoadjuvant chemotherapy. HER2 overexpression was determined immunohistochemically and/or using fluorescence in situ hybridization. RESULTS: pCR was achieved in 5.7% of luminal tumors (n = 8730), 24.6% of HER2-positive tumors (n = 4403), and 18.9% of triple-negative tumors (n = 3660). Among HER2-positive tumors, pCR was achieved in 31.6% of ER-negative tumors (n = 2252), 17.0% of ER-positive ones (n = 2132), 31.4% of patients who received trastuzumab as neoadjuvant chemotherapy (n = 2437), and 16.2% of patients who did not receive trastuzumab (n = 1966). Of the 2811 patients who were HER2-positive before treatment, 601 (21.4%) had HER2-negative tumors after neoadjuvant chemotherapy, whereas 340 (3.4%) of the 9947 patients with HER2-negative tumors before treatment had HER2-positive tumors afterward. Of the 10,973 patients with ER-positive tumors before treatment, 499 (4.6%) had ER-negative tumors after neoadjuvant chemotherapy, whereas 519 (9.3%) of the 5607 patients who were ER-negative before treatment had ER-positive tumors afterward. CONCLUSION: We confirmed that loss of HER2-positive status can occur after neoadjuvant treatment in patients with primary HER2-positive breast cancer. We also confirmed that in practice, differences in pCR rates between breast cancer subtypes are the same as in clinical trials. Our data strongly support the need for retest ER, PgR, HER2 of surgical sample after neoadjuvant therapy in order to accurately determine appropriate use of targeted therapy.
Authors: Srivarshini Cherukupalli Mohan; Sarah Walcott-Sapp; Minna K Lee; Marissa K Srour; Sungjin Kim; Farin F Amersi; Armando E Giuliano; Alice P Chung Journal: Ann Surg Oncol Date: 2021-03-21 Impact factor: 5.344
Authors: Farrokh Dehdashti; Ningying Wu; Ron Bose; Michael J Naughton; Cynthia X Ma; Bernadette V Marquez-Nostra; Philipp Diebolder; Cedric Mpoy; Buck E Rogers; Suzanne E Lapi; Richard Laforest; Barry A Siegel Journal: Breast Cancer Res Treat Date: 2018-02-13 Impact factor: 4.872
Authors: Francisco P Branco; Duarte Machado; Filipa F Silva; Saudade André; Ana Catarino; Rosa Madureira; João M Pinto; João P Godinho; Pedro D Simões; Margarida Brito; Mafalda Casa-Nova; António R Moreira; José L Passos-Coelho Journal: Am J Transl Res Date: 2019-09-15 Impact factor: 4.060
Authors: Lauren Brown; Samer A Naffouje; Christine Sam; Christine Laronga; M Catherine Lee Journal: Breast Cancer Res Treat Date: 2022-10-08 Impact factor: 4.624
Authors: Kevin M Turner; Syn Kok Yeo; Tammy M Holm; Elizabeth Shaughnessy; Jun-Lin Guan Journal: Am J Physiol Cell Physiol Date: 2021-06-30 Impact factor: 5.282